[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

March 23, 2017
Editorial

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor From Lumping to Splitting

Abstract Full Text
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2016.5740
Original Investigation

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant ImatinibAn Exploratory Analysis of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2016.5751

This exploratory analysis of a randomized clinical trial investigates the effect of KIT and PDGFRA mutations on recurrence-free survival in a population of patients with gastrointestinal stromal tumors treated with surgery and adjuvant imatinib.

Birth Outcomes Among Adolescent and Young Adult Cancer Survivors

Abstract Full Text
free access
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2017.0029

This case-control cohort study compares the birth outcomes of adolescent and young adult cancer survivors with those of women without a cancer diagnosis.

Brief Report

Association of HIV Status With Local Immune Response to Anal Squamous Cell CarcinomaImplications for Immunotherapy

Abstract Full Text
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2017.0115

This study compares the local tumor immune microenvironment in anal squamous cell carcinomas from HIV-positive and HIV-negative patients.

Review

Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and TreatmentA Review

Abstract Full Text
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2016.7013

This review investigates recent advances in the understanding of the genetics of small cell carcinoma of the urinary bladder and the potential implications in diagnosis, prognosis, and treatment.

Comment & Response

Risk of Bias and Heterogeneity—Reply

Abstract Full Text
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2017.0160

Risk of Bias and Heterogeneity

Abstract Full Text
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2017.0164
Correction

Missing Author Initial in Byline

Abstract Full Text
free access
JAMA Oncol. Published online March 23, 2017. doi:10.1001/jamaoncol.2017.0705
March 16, 2017
Viewpoint

To ProtecT Our Patients With Prostate Cancer

Abstract Full Text
JAMA Oncol. Published online March 16, 2017. doi:10.1001/jamaoncol.2017.0274

This Viewpoint examines the conclusions of the ProtecT randomized clinical trial and argues that, instead of radical therapy, appropriate patients for active surveillance should be chosen and active surveillance strategies optimized to avoid the small increased risk of distant metastasis seen in ProtecT.

Original Investigation

Brain Metastases in Newly Diagnosed Breast CancerA Population-Based Study

Abstract Full Text
JAMA Oncol. Published online March 16, 2017. doi:10.1001/jamaoncol.2017.0001

This population-based cohort study uses the SEER database to characterize the incidence proportion of brain metastases at the time of cancer diagnosis among patients with breast cancer on a population-based level.

Review

Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast CancerA Review

Abstract Full Text
JAMA Oncol. Published online March 16, 2017. doi:10.1001/jamaoncol.2016.4975

This review examines androgen receptor (AR)-related pathways, specific AR-targeted therapies, and the development of predictive biomarkers to stratify patients by likelihood of response to AR-targeted therapies.

March 9, 2017
Editorial

Planning Adjuvant Trials When Regimens Effective for Patients With Advanced Disease Don’t Work in the Adjuvant Setting—Paradigms Lost

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0066
Original Investigation

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

Abstract Full Text
open access
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0013

This study compares the performance of 4 programmed cell death ligand 1 platforms, including 2 assays cleared by the US Food and Drug Administration and 2 laboratory-developed tests.

Association of the Timing of Pregnancy With Survival in Women With Breast Cancer

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0248

This study compares the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant.

Patients’ and Parents’ Needs, Attitudes, and Perceptions About Early Palliative Care Integration in Pediatric Oncology

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0368

This survey evaluates pediatric patients’ and parents’ perceptions of symptom burden during early cancer treatment and assesses their attitudes toward early integration of palliative care in pediatric oncology.

Brief Report

Adjuvant Treatment for High-Risk Clear Cell Renal CancerUpdated Results of a High-Risk Subset of the ASSURE Randomized Trial

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0076

This updated analysis of a subset in the ASSURE clinical trial examines the disease-free survival and overall survival of high-risk patients with clear cell renal cancer treated with sunitinib, sorafenib, or placebo.

Invited Commentary

Assays for PD-L1 ExpressionDo All Roads Lead to Rome?

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0012

Pediatric Palliative Care—A Shared Priority

Abstract Full Text
JAMA Oncol. Published online March 9, 2017. doi:10.1001/jamaoncol.2017.0351
March 2, 2017
Original Investigation

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerThe Randomized Clinical FinXX Trial

Abstract Full Text
open access
JAMA Oncol. Published online March 2, 2017. doi:10.1001/jamaoncol.2016.6120

This randomized clinical trial compares 10-year survival rates for 2 adjuvant combination therapies for early breast cancer: docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil vs docetaxel plus capecitabine followed cyclophosphamide, epirubicin, and capecitabine.

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related FatigueA Meta-analysis

Abstract Full Text
JAMA Oncol. Published online March 2, 2017. doi:10.1001/jamaoncol.2016.6914

This meta-analysis establishes weighted effect sizes to compare exercise, psychological, combined exercise and psychological, and pharmaceutical interventions to treat cancer-related fatigue among patients with cancer during and after therapy.

Brief Report

Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease

Abstract Full Text
JAMA Oncol. Published online March 2, 2017. doi:10.1001/jamaoncol.2017.0041

This medical record review assesses the clinical and radiologic responses to cladribine for the treatment of adults with Erdheim-Chester disease.

JAMA Oncology Clinical Challenge

Rapidly Enlarging Thyroid Mass in a Patient With History of Multiple Cancers

Abstract Full Text
JAMA Oncol. Published online March 2, 2017. doi:10.1001/jamaoncol.2016.7084

A woman in her 30s presented with a palpable, nontender, firm mass in the neck. She had a medical history of high-grade osteosarcoma with areas of leimyosarcoma of the tibia. What is your diagnosis?

×